As elevated interstitial flow and abnormal angiogenesis are extensive in pathologies such as cancer, understanding how ECs sense and respond to flow via HDAC1 will not only advance our knowledge of the role of mechanotranduction and chromatin remodeling in angiogenesis, but also open up the possibilities of designing novel anti-angiogenic drugs and regimens to advance cancer therapies. This evidence concerns the gene HDAC1 and cancer.